hero-image-mobile

Let's Build Better Cells Together

Navigate your way from concept to clinic by partnering with MaxCyte®.

We've spent over 20 years perfecting the art of cell engineering and venturing beyond today's process to innovate tomorrow's solutions. Our ExPERT™ instruments feature best-in-class electroporation technology combining high efficiency and cell viability with seamless scalability, all backed by a global team of technical and regulatory experts providing ongoing support.

We provide the spark of collaboration empowering research into treatments and cures that will transform human health. Chart your best course with MaxCyte.

We are thrilled to support CRISPR Therapeutics and Vertex Pharmaceuticals in celebrating the approval of their MaxCyte-enabled groundbreaking CRISPR/Cas9 gene-edited cell therapy, CASGEVY™ for the treatment of sickle cell disease. Learn More...

Research Applications

Cell Therapy

Discover scalable engineering to enable safe and potent cell therapies.

Cell Based Assays

Produce assay-ready cells faster with scalable electroporation.

Antibody & Protein Production

Accelerate biotherapeutic development with transient expression for gram-scale protein production.

Viral Vector Production

Transfect adherent or suspension cells to produce a variety of viral vectors.

Gene Editing

Navigate the complexities of genome engineering with highly efficient delivery.

Vaccine Development

Innovate vaccine research with our adaptable platform for production of recombinant proteins, virus-like particles and more.

Explore the research we've supported

See how MaxCyte technology is advancing our partners' biomedical innovations

CET-app-note@2x
Application Note
Triple-Engineered NYCE cells as T Cell Therapy for Refractory Cancers
DNA-Nanovector@2x
Poster
Clinical Scale Delivery of nS/MARt Vectors for CAR T Cell Engineering
MAR-app-note@2x
Application Note
Highly Efficient CAR T Cell Engineering, with CRISPR and Single-Stranded Cas9 Target Sequences.

We're here throughout your journey

Because bringing a new therapeutic to market is a long and complex endeavor, we offer our expertise to support your innovations and chart a more direct course to success.

The benefits of our collaborative approach can be seen in over 35 clinical trials. Our technology has enabled studies by leaders in pharmaceutical and biotechnology research developing treatments for a variety of indications including cancer, heart disease, central nervous system disorders and rare genetic diseases.

Maxcyte

Resources

MaxCyte_Icons_-scientific-brief
Scientific Briefs
MaxCyte_Icons_-webinars
Webinars
MaxCyte_Icons_-poster
Scientific Posters
MaxCyte_Icons_-app-note
App Notes
MaxCyte_Icons_-primary-literature
Literature

MaxCyte News

MaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugen’s Investigational Allogeneic, Off-the-Shelf Cell Therapies for Cancers

FEATURED NEWS

January 30, 2024

Latest News